Clinical Trials - RNAC

NCT IDTitleStatusPhasesStart DateCompletion DatePrimary Completion Date
NCT07089121Descartes-08 for Children, Adolescents and Young Adults With Childhood-onset Systemic Lupus Erythematosus, ANCA-associated Vasculitis, Juvenile Myasthenia Gravis, and Juvenile DermatomyositisNOT_YET_RECRUITINGPHASE1, PHASE22025-122026-122026-12
NCT06799247Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia GravisRECRUITINGPHASE32025-05-062027-09-302026-11-30
NCT06304636Descartes-15 for Patients With Relapsed/Refractory Multiple MyelomaACTIVE_NOT_RECRUITINGPHASE12024-06-192027-10-012026-12-01
NCT06038474Descartes-08 for Patients With Systemic Lupus ErythematosusRECRUITINGPHASE22024-02-122026-11-012025-11-01
NCT04816526Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction TherapyTERMINATEDPHASE22021-12-012022-11-032022-08-04
NCT05113342Descartes-25 in Relapsed/Refractory Multiple MyelomaTERMINATEDPHASE12021-11-252024-11-082023-05-09
NCT04436029Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction TherapyCOMPLETEDPHASE22021-02-242022-04-092022-02-18
NCT04524962Study of Descartes-30 in Acute Respiratory Distress SyndromeTERMINATEDPHASE12021-02-232023-09-092022-09-09
NCT04146051Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)ACTIVE_NOT_RECRUITINGPHASE22019-12-042026-03-312025-07-31
NCT03994705Descartes-11 in Patients With Relapsed/Refractory Multiple MyelomaTERMINATEDPHASE12019-08-012021-06-112021-05-27
NCT03448978Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With MyelomaTERMINATEDPHASE12018-03-082021-06-032021-04-19